SecBot SecBot
PRESS-RELEASE ·Filed Apr 6, 2026

CLDX

Celldex Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Activist
Actionable Insight • Neutral

While the capital raise strengthens Celldex’s balance sheet for clinical development, the lack of near-term catalysts or data readouts suggests limited immediate upside. Traders should monitor pipeline advancement and future dilution risk given the company's pre-revenue status.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.37
T+0 close · Apr 6, 2026 · via day close
Latest settled
+17.25%
T+60 · $36.78
Vs SPY
+3.78%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $31.37entry
  2. T+1 · 7mo ago −0.06%α −0.13% · $31.35
  3. T+5 · 7mo ago +3.89%α −0.25% · $32.59
  4. T+20 · 7mo ago +4.46%α −4.52% · $32.77
  5. T+60 · 5mo ago +17.25%α +3.78% · $36.78
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Celldex Therapeutics closed an underwritten public offering of 11.9 million shares at $29.00 per share, raising approximately $345 million in gross proceeds. The capital will support the company's clinical-stage biotech pipeline focused on mast cell biology and immune system therapeutics.

Key Financial Metrics

Deal Value
$345.0M

Key Facts

  • Celldex closed a public offering of 11,896,750 common shares, including full exercise of the underwriters' option for 1,551,750 additional shares.
  • Offering price was $29.00 per share, resulting in gross proceeds of approximately $345 million.
  • Proceeds will be used for general corporate purposes, including advancing Celldex’s clinical-stage pipeline in inflammatory, allergic, and autoimmune diseases.
  • Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor acted as joint bookrunners; LifeSci Capital and H.C. Wainwright as co-lead managers.
  • The offering was made under an effective shelf registration (Form S-3, File No. 333-275300) and completed via prospectus supplement.

Financial Impact

$345 million in gross proceeds, with no immediate dilution impact factored into stock price post-offering

cashdilutionequity

Risk Factors

  • Dilution from the issuance of new shares could pressure stock price despite strong gross proceeds.
  • As a clinical-stage biotech with no commercial products, Celldex remains highly dependent on trial outcomes and future funding rounds.

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3268530

Track record

21 reports on CLDX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +19.96% at T+20 after the Jun 14, 2026 report. 4 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 Now $28.59 −1.31% settles Feb 12
  2. Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
  3. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 Now $28.59 −3.77% settles Feb 1
  5. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 Now $28.59 −6.05% settles Jan 4
  6. Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
  7. Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
  8. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
  9. Jun 14, 202622w ago Press Release Bearish 6/10 Entry $32.12 to $38.10 Now $28.59 +10.99% ▼ −18.62% −18.22% vs SPY
  10. Jun 14, 202622w ago Press Release Bullish 7/10 Entry $32.12 to $38.10 Now $28.59 −10.99% ▲ +18.62% +18.22% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (11h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 6, 2026